New Drug Development Process

There are multiple processes in new drug development, and efficacy must be evaluated. Clinical trials are typically organized into three phases (Phase I–III) and are conducted at investigational sites (e.g., hospitals and other medical institutions) under strict criteria and with the informed consent of participants.

In general, the path from discovery of a candidate compound to approval requires more than 10 years. Within this extended process, clinical trials are a key step that supports the regulatory approval application.

The process and duration of new drug development

New drug development proceeds over an extended timeline. First, basic research identifies candidate compounds. In this stage, chemical and biological approaches are used to pinpoint molecules with potential efficacy.

The next step is non-clinical testing. Here, the efficacy of the drug is evaluated using animal models and cultured cells. SubsequentData obtained in each phase of the clinical trial is used to file for regulatory approval

Although the pathway is lengthy, each stage must be completed to deliver an effective drug.

The importance of nonclinical studies

Non-clinical testing is a very important step in new drug development. Taking sufficient time in this stage is an important strategy to reduce subsequent development risks. By proceeding cautiously through this phase, as animals and cultured cells are used to evaluate the drug's efficacy,Reduces the risk of unforeseen events and failures in clinical trials involving human subjects

By carefully conducting non-clinical studies,More accurate prediction of the effects and side effects of new drug candidates on humans, enabling the development of more effective drugsThis is the first step in the development process. This time spent on non-clinical trials avoids the loss of expensive R&D costs in later clinical trial stages and improves the overall efficiency of development, making it easier to guarantee the efficacy and effectiveness of the drug that is ultimately brought to market.

Summary

New drug development is a complex, resource-intensive process. Each step—from basic research to nonclinical studies to clinical trials—plays a distinct role.

In particular, investing time in nonclinical studies can reduce risk and support more efficient development. To substantiate the efficacy and effectiveness of a new drug, these testing processes must be executed rigorously.